| P50 | author | Mariam A Ahmed | Q87210588 |
| P2093 | author name string | Richard C Brundage | |
| | Ali A Alhadab | |
| P2860 | cites work | Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 |
| | Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD) | Q57238270 |
| | “Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy | Q63859738 |
| | Amikacin, Ceftazidime, and Flucloxacillin against Suspended and Adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an In Vitro Model of Infection | Q67728880 |
| | Use of an in-vitro kinetic model to study antibiotic combinations | Q69940704 |
| | Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside | Q73167979 |
| | The pharmacodynamics of aminoglycosides | Q74802269 |
| | Population pharmacokinetics of amikacin in patients with haematological malignancies | Q78207215 |
| | Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models | Q30499990 |
| | Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint | Q30620954 |
| | Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults | Q33692660 |
| | Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock | Q33919190 |
| | Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children | Q34106577 |
| | The antibiotic resistance crisis: part 1: causes and threats | Q34471028 |
| | Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model | Q35117352 |
| | Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue | Q35754443 |
| | Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model | Q35819487 |
| | Optimizing the initial amikacin dosage in adults | Q36158283 |
| | Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy | Q36753828 |
| | Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model | Q36758305 |
| | Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development | Q36949430 |
| | Bacterial uptake of aminoglycoside antibiotics. | Q37063992 |
| | Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures. | Q37160830 |
| | Assessment of gentamicin 7 mg/kg once daily for pediatric patients with febrile neutropenia: a pilot project | Q37411815 |
| | Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs | Q38117228 |
| | Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization | Q38626980 |
| | What about confidence intervals? A word of caution when interpreting PTA simulations. | Q38871384 |
| | Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling | Q39300554 |
| | In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates | Q39674263 |
| | Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 |
| | Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. | Q41696202 |
| | The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance | Q42956779 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients | Q44484329 |
| | Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections | Q45265803 |
| | Single daily dosing of amikacin in an in-vitro model. | Q54297042 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | amikacin | Q408529 |
| | pharmacodynamics | Q725307 |
| P577 | publication date | 2018-01-22 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients | |
| P478 | volume | 62 | |